JDS-HF3.0 Supplementation for Menopause Symptoms
This study is testing whether a dietary supplement called JDS-HF3.0 can improve the quality of life for women experiencing menopause symptoms, such as joint discomfort and hot flashes. Researchers want to see if taking JDS-HF3.0 daily for 12 weeks reduces the severity and frequency of these symptoms. You may be able to join if you are a healthy woman between 50 and 70 years old, have a BMI between 18.5 and 34.9, and have been postmenopausal for at least 12 months naturally. The study will be considered successful if participants taking JDS-HF3.0 show an improvement in their menopause-related quality of life compared to those taking a placebo. The current recruitment status is unclear.
- Study design
- This is an interventional study where about 250 women will be randomly assigned to take either the active supplement JDS-HF3.0 or a nonactive placebo.
- What's involved
- You will take two tablets each morning for about 12 weeks. The total study time is about 14 weeks, including five virtual check-ins and completing daily diaries and weekly/monthly questionnaires.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from enrollment to the end of the study at 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from Baseline in Menopause Related Quality of Life OutcomesFrom enrollment to the end of study at 12 weeks
Change from baseline in scores for severity of perceived joint discomfort, frequency of perceived joint discomfort, perceived joint mobility and perceived daily mobility assessed via a Visual Analog Scale (VAS). Response options will range from 0-100, with a higher score reflecting the worse outcome.
- Change from Baseline in Menopause Related Quality of Life OutcomesFrom enrollment to the end of study at 12 weeks
Change from baseline in scores for Arthralgia Inventory (PRAI) score. The rating scale ranges from 0-10, with a higher score indicating a worse outcome.
- Change from Baseline in Menopause Related Quality of Life OutcomesFrom enrollment to the end of study at 12 weeks
Change from baseline in scores for Musculoskeletal Health Questionnaire (MSK-HQ) score. Each response ranges from "not at all" to "very severe", with a higher score indicating a better outcome.